The Delhi High Court’s decision in Array Biopharma Inc. v. Deputy Controller of Patents highlights a basic but important point: patent objections must be tied to the claims and evidence, not merely asserted. Harsh Kashyap explains how the Court applied
Mr. P. H. Kurian (1959-2026)
It is with great sorrow that we share that the Indian IP fraternity lost one of its most remarkable administrators, Mr. P. H. Kurian, yesterday after a battle with cancer. A 1986-batch IAS officer, Mr.
A recent Bombay High Court decision adds an important procedural dimension to the growing judicial scrutiny of how Controllers assess obviousness. Maneesha Gupta explains how in Ashit Padhaya v. Assistant Controller of Patents and Designs, the problem was not the
When a court finds that its interim injunction has been wilfully breached, should punishment necessarily follow? Harsh Kashyap explores this in light of the Bombay High Court decision in KVIC v. Jaishukh N. Bhuta, explaining how the Court draws an
The Delhi High Court’s decision to appoint an amicus curiae to represent Vivek Oberoi’s perspective after his counsel withdrew raises an unusual procedural question in a civil suit pertaining to the right of publicity. This tidbit by Vishwas Kumar Tripathi
Welcome back to another week of Bells & Whistles.
As always, we’ve rounded up a mix of developments, opportunities, and thoughtful reads from across the IP world along with a Bell of the Week that’s well worth revisiting.
Bell of
Starting the week with our weekly roundup of key IP developments and posts on Mavyret patent abandonment, calls for comments on new patent and trademark manuals, and the DHC’s decision in Intra Cellular Therapies v. Controller. This and a lot
July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from India by 2030 through free testing and access to generic versions
The office of the Controller General of Patents, Designs and Trademarks (CGPDTM) has released two new notifications regarding updates to the office manuals. Yesterday, the office invited comments and suggestions from stakeholders on the Draft Manual of Patent Office (Practice &
In Intra Cellular Therapies v. Controller of Patents, the Delhi High Court revisited two recurring fault lines in pharmaceutical patent law: the coverage disclosure distinction in genus-species claims and the therapeutic efficacy threshold under Section 3(d). Arnav Kaman argues that
